SARS-CoV-2 Nucleic Acid Detection Kit (PCR-Fluorescent Probe Method)
May 10, 2021 Zybio News
-
Jun 27, 2025
DiagHub Online Academic Platform: The third session on POCT Concludes Successfully – Highlights Recap
-
May 30, 2025
DiagHub Online Academic Platform: The second session on Immunology Concludes Successfully
-
May 28, 2025
Conference Summary | 3rd Conference on Innovative Technology Applications in Laboratory Medicine: Exploring the Source of Mass Spectrometry, Advancing the Path of Innovation
On April 1st, SARS-CoV-2 Nucleic Acid Detection Kit (PCR-Fluorescent Probe Method) developed by Zybio obtained the medical device registration certificate of CFDA.
According to the Work Manual of Nucleic Acid Testing for SARS-CoV-2 in Medical Institutions released by Joint Prevention and Control Mechanism of the State Council on December 28th, 2020, it is recommended to use reagents with high sensitivity (LoD ≤500 copies/ml) and above the double target area for detection, and use the matching VTM and extraction kits recommended in the IFU.
Primers and probes for SARS-CoV-2 nucleic acid detection
Furthermore, As early as March 9th, 2020, Zybio has obtained the CE certification of SARS-CoV-2 Nucleic Acid Detection Kit, providing VTM, automatic nucleic acid isolation system EXM3000, EXM6000, and nucleic acid extraction and detection kit for nearly 100 countries including ASEAN countries. Zybio's molecular products will continue to fight against the global COVID-19 pandemic and protect human health.